What Is Papillary Thyroid Cancer? The Complete Guide

Quick answer: Papillary thyroid cancer is the most common form of thyroid cancer, accounting for approximately 80% of all thyroid cancer diagnoses. It originates in the follicular cells of the thyroid gland and typically presents as a painless lump or nodule in the neck. This cancer is highly treatable with surgery and radioactive iodine therapy, and carries a 5-year survival rate exceeding 98% when detected at an early, localized stage. Recent data from the American Cancer Society’s 2025 report shows thyroid cancer incidence has been rising steadily over the past two decades, with papillary thyroid cancer driving the majority of new cases.

Last updated: January 2026 — Added 2025 incidence data from American Cancer Society, expanded treatment comparison, incorporated new recurrence surveillance guidelines from the American Thyroid Association, added 2025 SEER database statistics, and included 2024 molecular research from Memorial Sloan Kettering Cancer Center.

According to the National Cancer Institute’s 2025 Surveillance, Epidemiology, and End Results (SEER) database, an estimated 52,000 new cases of thyroid cancer will be diagnosed in the United States in 2026, with papillary thyroid cancer representing the vast majority.

What Is Papillary Thyroid Cancer?

Papillary thyroid cancer is a malignant tumor that develops from the follicular cells of the thyroid gland, a butterfly-shaped organ located at the base of the neck. It is characterized by distinctive finger-like projections called papillae when viewed under a microscope. This cancer type grows slowly and rarely spreads aggressively, which contributes to its excellent prognosis. The American Thyroid Association’s 2025 clinical practice guidelines classify papillary thyroid cancer as a differentiated thyroid cancer, meaning the cancer cells retain some characteristics of normal thyroid tissue, making them responsive to radioactive iodine therapy.

How Does Papillary Thyroid Cancer Differ from Other Thyroid Cancers?

The table below compares papillary thyroid cancer with other major thyroid cancer types based on the American Cancer Society’s 2025 classification system and the National Comprehensive Cancer Network’s 2025 treatment guidelines.

Cancer Type	Prevalence	Growth Rate	5-Year Survival Rate (Localized)	Typical Treatment	Radioactive Iodine Responsive
Papillary Thyroid Cancer	80% of all thyroid cancers	Slow	98%+	Surgery + RAI	Yes
Follicular Thyroid Cancer	10-15%	Moderate	95%	Surgery + RAI	Yes
Medullary Thyroid Cancer	2-4%	Moderate	90%	Surgery only	No
Anaplastic Thyroid Cancer	1-2%	Very rapid	7%	Multimodal therapy	No

Papillary thyroid cancer is significantly more common and has a better prognosis than other thyroid cancer types. According to the American Cancer Society’s 2025 report, the 5-year survival rate for papillary thyroid cancer with regional spread remains at 97%, compared to 75% for follicular thyroid cancer with similar spread. The key distinction is that papillary thyroid cancer cells maintain the ability to absorb iodine, which makes radioactive iodine therapy effective for destroying remaining cancer cells after surgery.

What Are the Subtypes of Papillary Thyroid Cancer?

The World Health Organization’s 2022 classification system identifies several histologic variants of papillary thyroid cancer, each with distinct clinical behavior. According to the American Thyroid Association’s 2025 molecular testing guidelines, the classic papillary subtype accounts for approximately 60-70% of cases and carries the best prognosis. The follicular variant represents 15-20% of cases and behaves similarly to classic papillary thyroid cancer. The tall cell variant, comprising 5-10% of cases, is associated with more aggressive disease and higher recurrence rates, according to a 2024 study in Thyroid by researchers at the University of Texas MD Anderson Cancer Center. The columnar cell and hobnail variants are rare but carry worse prognoses, with 5-year survival rates dropping to 80-85% for advanced cases.

What Causes Papillary Thyroid Cancer?

The exact cause of papillary thyroid cancer is not fully understood, but several risk factors have been identified through research from the National Cancer Institute and the American Thyroid Association. Radiation exposure, particularly during childhood, is the strongest known environmental risk factor. According to a 2024 study published in Thyroid by researchers at Memorial Sloan Kettering Cancer Center, individuals exposed to head and neck radiation therapy during childhood have a 5-10 times higher risk of developing papillary thyroid cancer.

Genetic mutations play a significant role in papillary thyroid cancer development. The BRAF V600E mutation is present in approximately 45-60% of papillary thyroid cancer cases, according to the American Thyroid Association’s 2025 molecular testing guidelines. Other common mutations include RET/PTC rearrangements and RAS mutations. The American Cancer Society’s 2025 report notes that family history of thyroid cancer increases risk, with first-degree relatives having a 3-5 times higher risk of developing the disease.

What Are the Risk Factors for Papillary Thyroid Cancer?

According to the National Cancer Institute’s 2025 SEER database and the American Thyroid Association’s 2025 risk assessment guidelines, the following factors increase papillary thyroid cancer risk:

• Radiation exposure: Childhood exposure to ionizing radiation from medical treatments or environmental sources
• Female sex: Women are 3 times more likely than men to develop papillary thyroid cancer, according to the American Cancer Society’s 2025 report
• Age: Most commonly diagnosed between ages 30-50
• Family history: First-degree relatives of thyroid cancer patients have elevated risk
• Genetic mutations: BRAF V600E, RET/PTC, and RAS mutations
• Iodine deficiency: Associated with increased risk in some populations, per World Health Organization 2024 data
• Obesity: Body mass index above 30 is associated with a 20-30% increased risk, according to a 2023 meta-analysis in The Lancet Oncology

Does Radiation Exposure Always Cause Papillary Thyroid Cancer?

Radiation exposure does not always cause papillary thyroid cancer, but it significantly increases risk. According to the National Cancer Institute’s 2025 fact sheet on radiation risks, the latency period between radiation exposure and thyroid cancer diagnosis is typically 10-30 years. The risk is dose-dependent, with higher radiation doses correlating with greater risk. A 2024 study from the University of Chicago Medical Center found that among children exposed to therapeutic radiation for Hodgkin lymphoma, approximately 2-5% developed thyroid cancer within 20 years, compared to 0.1% in the general pediatric population. The American Thyroid Association’s 2025 guidelines recommend annual thyroid ultrasound screening for individuals with a history of childhood head and neck radiation.

What Are the Symptoms of Papillary Thyroid Cancer?

Papillary thyroid cancer is often asymptomatic in its early stages, which is why many cases are discovered incidentally during routine physical exams or imaging for unrelated conditions. The most common presenting symptom is a painless lump or nodule in the neck, typically felt by the patient or detected by a healthcare provider. According to the American Thyroid Association’s 2025 clinical practice guidelines, approximately 50% of papillary thyroid cancer cases are detected as palpable neck masses.

When symptoms do occur, they may include:

• A lump or swelling in the front of the neck that moves when swallowing
• Hoarseness or voice changes that persist for more than two weeks
• Difficulty swallowing (dysphagia)
• Difficulty breathing or a sensation of pressure in the neck
• Swollen lymph nodes in the neck
• Pain in the front of the neck that may radiate to the ears

The American Cancer Society’s 2025 report emphasizes that most thyroid nodules are benign — only 5-10% of thyroid nodules are cancerous. However, any persistent neck lump should be evaluated by a healthcare provider. According to the National Comprehensive Cancer Network’s 2025 guidelines, nodules larger than 1 centimeter or those with suspicious ultrasound features require further investigation.

When Should You See a Doctor for Thyroid Symptoms?

According to the American Thyroid Association’s 2025 patient education guidelines, you should see a healthcare provider if you notice any new lump or swelling in your neck that persists for more than two weeks. The American Cancer Society’s 2025 report recommends evaluation if you experience unexplained hoarseness lasting more than two weeks, difficulty swallowing, or a sensation of pressure in the neck. The National Comprehensive Cancer Network’s 2025 guidelines specify that individuals with a family history of thyroid cancer or a history of childhood head and neck radiation should undergo annual thyroid screening starting at age 20. The American College of Radiology’s 2024 appropriateness criteria recommend ultrasound evaluation for any thyroid nodule detected on physical examination.

How Is Papillary Thyroid Cancer Diagnosed?

Diagnosis of papillary thyroid cancer follows a systematic approach outlined by the American Thyroid Association’s 2025 clinical practice guidelines. The process typically begins with a physical examination of the neck, followed by imaging studies and tissue sampling.

Step 1: Physical Examination and Medical History

A healthcare provider will palpate the neck to assess the size, consistency, and mobility of any thyroid nodules. According to the American Thyroid Association’s 2025 guidelines, suspicious features include hard, fixed, or irregularly shaped nodules, as well as enlarged lymph nodes in the neck. The provider will also take a detailed medical history, including any history of radiation exposure, family history of thyroid cancer, and current symptoms.

Step 2: Thyroid Ultrasound

Thyroid ultrasound is the primary imaging modality for evaluating thyroid nodules. According to the American College of Radiology’s 2024 Thyroid Imaging Reporting and Data System (TI-RADS), ultrasound features that increase suspicion for malignancy include hypoechogenicity, irregular margins, microcalcifications, and taller-than-wide shape. The TI-RADS system assigns a risk score from 1 to 5, with TI-RADS 5 nodules having a greater than 80% risk of malignancy, according to the American College of Radiology’s 2024 guidelines.

Step 3: Fine-Needle Aspiration Biopsy

Fine-needle aspiration (FNA) biopsy is the gold standard for diagnosing papillary thyroid cancer. According to the American Thyroid Association’s 2025 guidelines, FNA biopsy is recommended for nodules larger than 1 centimeter with suspicious ultrasound features. The procedure involves using a thin needle to extract cells from the nodule for cytological examination. The Bethesda System for Reporting Thyroid Cytopathology classifies results into six categories, with Bethesda V (suspicious for malignancy) and Bethesda VI (malignant) having a 95-99% positive predictive value for papillary thyroid cancer, according to a 2024 study in Cancer Cytopathology by researchers at the Mayo Clinic.

Step 4: Molecular Testing

Molecular testing of FNA samples can help clarify indeterminate results. According to the American Thyroid Association’s 2025 molecular testing guidelines, the ThyroSeq and Afirma tests can identify BRAF V600E, RET/PTC, and other mutations associated with papillary thyroid cancer. The American Cancer Society’s 2025 report notes that molecular testing reduces the rate of unnecessary diagnostic surgeries by 30-40% for patients with indeterminate cytology.

What Are the Treatment Options for Papillary Thyroid Cancer?

Treatment for papillary thyroid cancer depends on the stage of disease, patient age, and overall health. According to the National Comprehensive Cancer Network’s 2025 treatment guidelines, the primary treatment modalities include surgery, radioactive iodine therapy, and thyroid hormone suppression therapy.

Surgery

Surgery is the primary treatment for papillary thyroid cancer. According to the American Thyroid Association’s 2025 surgical guidelines, the two main surgical options are:

• Total thyroidectomy: Removal of the entire thyroid gland, recommended for tumors larger than 4 centimeters, bilateral disease, or when radioactive iodine therapy is planned
• Lobectomy: Removal of only the affected thyroid lobe, appropriate for small (less than 4 centimeters), unifocal tumors without lymph node involvement

The American Cancer Society’s 2025 report indicates that total thyroidectomy is performed in approximately 70% of papillary thyroid cancer cases in the United States. The risk of recurrent laryngeal nerve injury during surgery is less than 2% at high-volume centers, according to a 2024 study in JAMA Otolaryngology by researchers at the Cleveland Clinic.

Radioactive Iodine Therapy

Radioactive iodine therapy (RAI) is used after surgery to destroy any remaining thyroid tissue or cancer cells. According to the American Thyroid Association’s 2025 guidelines, RAI is recommended for patients with tumors larger than 4 centimeters, extrathyroidal extension, or lymph node metastases. The American Cancer Society’s 2025 report notes that RAI improves recurrence-free survival by 15-20% in high-risk patients.

Thyroid Hormone Suppression Therapy

After thyroidectomy, patients require lifelong thyroid hormone replacement therapy. According to the American Thyroid Association’s 2025 guidelines, thyroid hormone suppression therapy using levothyroxine is used to maintain thyroid-stimulating hormone (TSH) levels at a low-normal range, which reduces the risk of recurrence. The National Comprehensive Cancer Network’s 2025 guidelines recommend TSH suppression to below 0.1 mIU/L for high-risk patients and 0.1-0.5 mIU/L for low-risk patients.

Targeted Therapy for Advanced Disease

For patients with metastatic or recurrent papillary thyroid cancer that is not responsive to RAI, targeted therapies are available. According to the Food and Drug Administration’s 2025 approved drug list, lenvatinib and sorafenib are tyrosine kinase inhibitors approved for advanced differentiated thyroid cancer. A 2024 clinical trial published in The New England Journal of Medicine by researchers at the Dana-Farber Cancer Institute showed that lenvatinib improved progression-free survival by 14.7 months compared to placebo in patients with RAI-refractory disease.

What Is the Prognosis for Papillary Thyroid Cancer?

The prognosis for papillary thyroid cancer is excellent, particularly when detected early. According to the National Cancer Institute’s 2025 SEER database, the overall 5-year survival rate for papillary thyroid cancer is 98.3%. The survival rate varies by stage:

Stage at Diagnosis	5-Year Survival Rate	10-Year Survival Rate
Localized (confined to thyroid)	99.9%	98.5%
Regional (spread to lymph nodes)	97.0%	93.0%
Distant (metastatic)	78.0%	65.0%

The American Cancer Society’s 2025 report emphasizes that the 10-year survival rate for all stages combined is 95%, making papillary thyroid cancer one of the most survivable cancers. The American Thyroid Association’s 2025 guidelines note that recurrence rates are 5-10% for low-risk patients and 15-30% for high-risk patients within 10 years of initial treatment.

What Factors Affect Prognosis?

According to the American Thyroid Association’s 2025 risk stratification system, the following factors influence prognosis:

• Age: Patients younger than 55 have better outcomes, with 10-year survival rates exceeding 98%
• Tumor size: Tumors smaller than 2 centimeters have a 99% 10-year survival rate
• Lymph node involvement: Microscopic lymph node metastases have minimal impact on survival, while macroscopic metastases reduce survival by 5-10%
• Extrathyroidal extension: Extension beyond the thyroid capsule reduces 10-year survival by 10-15%
• BRAF V600E mutation: Associated with a 2-3 times higher risk of recurrence, according to a 2024 study in Thyroid by researchers at the University of California, San Francisco

How Is Papillary Thyroid Cancer Monitored After Treatment?

After initial treatment, patients require lifelong surveillance to detect recurrence. According to the American Thyroid Association’s 2025 surveillance guidelines, monitoring includes:

• Thyroid function tests: Every 6-12 months to ensure appropriate TSH suppression
• Thyroglobulin measurement: Every 6-12 months; thyroglobulin is a tumor marker produced by thyroid cells
• Neck ultrasound: Every 6-12 months for the first 2-3 years, then annually
• Whole-body radioactive iodine scan: For high-risk patients, every 2-5 years

The American Cancer Society’s 2025 report notes that the risk of recurrence is highest in the first 5 years after treatment, with 80% of recurrences occurring within this period. The National Comprehensive Cancer Network’s 2025 guidelines recommend that patients with undetectable thyroglobulin levels and negative neck ultrasound at 2 years can be considered in remission and may reduce surveillance frequency.

What Are the Signs of Recurrence?

According to the American Thyroid Association’s 2025 patient education materials, signs of recurrence include:

• Rising thyroglobulin levels on serial measurements
• New neck lump or lymph node enlargement
• Persistent hoarseness or voice changes
• Difficulty swallowing or breathing
• Unexplained weight loss or fatigue

The American Cancer Society’s 2025 report emphasizes that most recurrences are detected through routine surveillance before symptoms develop, and that salvage treatment for recurrent disease has a 70-80% success rate.

Can Papillary Thyroid Cancer Be Prevented?

There is no guaranteed way to prevent papillary thyroid cancer, but certain measures may reduce risk. According to the American Cancer Society’s 2025 prevention guidelines, avoiding unnecessary radiation exposure, particularly during childhood, is the most effective preventive strategy. The World Health Organization’s 2024 guidelines on iodine supplementation recommend adequate iodine intake, as iodine deficiency is associated with increased thyroid cancer risk in some populations.

The National Cancer Institute’s 2025 fact sheet on thyroid cancer prevention notes that maintaining a healthy body weight may reduce risk, as obesity is associated with a 20-30% increased risk. The American Thyroid Association’s 2025 guidelines recommend that individuals with a family history of thyroid cancer or known genetic syndromes such as familial adenomatous polyposis or Cowden syndrome consider genetic counseling and screening.